Literature DB >> 19850228

Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer.

Manuel T Silva1, Françoise Portaels, Jorge Pedrosa.   

Abstract

The necrotising skin infection Buruli ulcer is at present the third most common human mycobacteriosis worldwide, after tuberculosis and leprosy. Buruli ulcer is an emergent disease that is predominantly found in humid tropical regions. There is no vaccine against Buruli ulcer and its treatment is difficult. In addition to the huge social effect, Buruli ulcer is of great scientific interest because of the unique characteristics of its causative organism, Mycobacterium ulcerans. This pathogen is genetically very close to the typical intracellular parasites Mycobacterium marinum and Mycobacterium tuberculosis. We review data supporting the interpretation that M ulcerans has the essential hallmarks of an intracellular parasite, producing infections associated with immunologically relevant inflammatory responses, cell-mediated immunity, and delayed-type hypersensitivity. This interpretation judges that whereas M ulcerans behaves like the other pathogenic mycobacteria, it represents an extreme in the biodiversity of this family of pathogens because of its higher cytotoxicity due to the secretion of the exotoxin mycolactone. The acceptance of the interpretation that Buruli ulcer is caused by an intracellular parasite has relevant prophylactic and therapeutic implications, rather than representing the mere attribution of a label with academic interest, because it prompts the development of vaccines that boost cell-mediated immunity and the use of chemotherapeutic protocols that include intracellularly active antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850228     DOI: 10.1016/S1473-3099(09)70234-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  36 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mycobacterium ulcerans infection (Buruli ulcer) on the face: a comparative analysis of 13 clinically suspected cases from the Democratic Republic of Congo.

Authors:  Delphin M Phanzu; Roger L Mahema; Patrick Suykerbuyk; Désiré-Hubert B Imposo; Linda F Lehman; Elie Nduwamahoro; Wayne M Meyers; Marleen Boelaert; Françoise Portaels
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

Review 3.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

4.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 5.  Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.

Authors:  Laure Guenin-Macé; Reid Oldenburg; Fabrice Chrétien; Caroline Demangel
Journal:  Cell Mol Life Sci       Date:  2014-01-21       Impact factor: 9.261

6.  Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.

Authors:  Ghislain Emmanuel Sopoh; Ange Dodji Dossou; Luc Valère Brun; Yves Thierry Barogui; Jean Gabin Houézo; Dissou Affolabi; Séverin Y Anagonou; Roch Christian Johnson; Luc Kestens; Françoise Portaels
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

7.  Mycobacterium liflandii outbreak in a research colony of Xenopus (Silurana) tropicalis frogs.

Authors:  J J Fremont-Rahl; C Ek; H R Williamson; P L C Small; J G Fox; S Muthupalani
Journal:  Vet Pathol       Date:  2010-11-29       Impact factor: 2.221

8.  In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.

Authors:  Sushim Kumar Gupta; Michel Drancourt; Jean-Marc Rolain
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

9.  Family relationship, water contact and occurrence of Buruli ulcer in Benin.

Authors:  Ghislain Emmanuel Sopoh; Yves Thierry Barogui; Roch Christian Johnson; Ange Dodji Dossou; Michel Makoutodé; Sévérin Y Anagonou; Luc Kestens; Françoise Portaels
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

10.  Amoebae as potential environmental hosts for Mycobacterium ulcerans and other mycobacteria, but doubtful actors in Buruli ulcer epidemiology.

Authors:  Sophie Gryseels; Diana Amissah; Lies Durnez; Koen Vandelannoote; Herwig Leirs; Johan De Jonckheere; Manuel T Silva; Françoise Portaels; Anthony Ablordey; Miriam Eddyani
Journal:  PLoS Negl Trop Dis       Date:  2012-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.